CTIC Share Price Performance
US$0
0.00 (0.00%)
Price US$0
Share Pricen/a
CTI BioPharma Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
CTIC Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
CTI BioPharma Corp. Key Details
Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
- -0.53
- 94.11%
- -91.38%
- -459.4%
About CTIC
- Founded
- 1991
- Employees
- 128
- CEO
- WebsiteView website
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. As of June 26, 2023, CTI BioPharma Corp. operates as a subsidiary of Swedish Orphan Biovitrum AB (publ).
